The Brand Name ETHINORM-P Has Generic Salt :: Norethisterone
ETHINORM-P Is From Company Bennet Ph. Priced :: Rs. 25.9
ETHINORM-P have Norethisterone is comes under Sub class Contraceptive Drugs of Main Class Reproductive System
Main Medicine Class:: Reproductive System Sub Medicine Class :: Contraceptive Drugs
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Breast cancer, Metropathia haemorrhagica (dysfunctional uterine bleeding), Premenstrual syndrome, Contraception, Endometriosis, Menorrhagia, Menopausal HRT
Drug Dose ::
Adult: PO Metropathia haemorrhagica (dysfunctional uterine bleeding): 1 tablet 3 times daily for 10 days. Menstruation occurs within 2-4 days after discontinuing treatment. Prophylaxis against recurrence of dysfunctional bleeding: If there are no signs of resumption of normal ovarian function recurrence must be anticipated. Cyclical bleeding can be established with 1 tablet twice daily from the 19th to the 26th day of the cycle. Premenstrual syndrome (including premenstrual mastalgia): 2-3 tablets daily from the 19th to the 26th day of the cycle. Treatment should be repeated for several cycles. Postponement of menstruation: 1 tablet three times daily, starting 3 days before the expected onset of menstruation. A normal period should occur 2-3 days after the patient has stopped taking tablets. Endometriosis (pseudo-pregnancy therapy): Long-term treatment is commenced on the 5th day of the cycle with 2 tablets daily for the first few weeks. In the event of spotting, the dosage is increased to 4, and, if necessary, 5 tablets daily. After bleeding has ceased, the initial dose is usually sufficient. Menorrhagia (hypermenorrhoea): 1 tablet 2-3 times a day from the 19th to the 26th day of the cycle (counting the first day of menstruation as day 1).
Severe hepatic dysfunction; undiagnosed vaginal bleeding; porphyria; pregnancy; previous idiopathic or current thromboembolism; thromboembolic disease; DVT.
Drug Precautions ::
Hypertension; CVS disease; hepatic impairment; epilepsy; lactation; new onset of migraine-type headache; asthma; renal impairment; history of clinical depression.
Drug Side Effects ::
Mental depression, cholestatic jaundice, porphyria, epilepsy, migraine, headache, breast discomfort, dizziness, nausea and vomiting, changes in libido, appetite and weight, breakthrough bleeding, changes in menstrual flow, amenorrhoea, oedema, rash, melasma or cholasma, acne, urticaria, abnormal LFTs, moodswings, insomnia, thrombotic and thromoembolic events, optic neuritis, altered lipid profile.
Pregnancy category ::
Drug Mode of Action ::
Norethisterone has typical effects of a progestogen and converts the endometrium from the proliferative to the secretory phase. It may also have some oestrogenic, anabolic and androgenic activities, but these may not be significant. Norethisterone delays onset of periods and controls abnormal uterine bleeding. It also has contraceptive effects due to negative feedback inhibition of pituitary gonadotropin thus preventing ovulation.
Drug Interactions ::
Concentration may be reduced by CYP450 inducers (e.g. phenobarbital, phenytoin, carbamazepine, rifampicin, rifabutin, nevirapine, efavirenz, tetracyclines, ampicillin, oxacillin, co-trimoxazole) and ritonavir, nelfinavir (usually inhibitors of CYP450 but have inducing properties when used with steroid hormones). May cause additive fluid retention with NSAIDs, vasodilators. Adjustment in antidiabetic, thyroid hormone and anticoagulant therapy may be required. Potentially Fatal: May increase ciclosporin concentration.